RESEARCH MONOGRAPH · KDC-MN-193

Exenatide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

77/100

The first incretin mimetic. Eclipsed clinically by newer agents but mechanistically fascinating and still useful

Exenatide is the synthetic version of exendin-4, the 39-amino-acid peptide isolated from Heloderma suspectum (Gila monster) saliva by John Eng in the early 1990s. It's the molecule that started the GLP-1 receptor agonist drug class. Around 53 percent sequence homology with native human GLP-1 but a much longer half-life because it resists DPP-4 cleavage at the N-terminus, which is why pharma went after exendin-based analogs in the first place.

Pharmacologically it's a textbook GLP-1 receptor agonist: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central effects on appetite. The original twice-daily formulation (Byetta) and the once-weekly extended-release (Bydureon) have been used clinically since 2005 and 2012 respectively. Reduces A1c by 0.8-1.5 percent typically and produces modest weight loss in the 2-4 kg range, which is meaningful but obviously dwarfed by semaglutide and tirzepatide.

What's most interesting about exenatide right now isn't diabetes, it's the neuroprotection literature. There are ongoing trials in Parkinson's disease following Tomas Foltynie's 2017 Lancet paper showing motor improvement that persisted after washout, which is a striking finding if it replicates. The PD-STAT and Exenatide-PD3 programs are extending that work. Mechanism is probably central GLP-1R signaling reducing neuroinflammation and possibly improving mitochondrial function in dopaminergic neurons. We dont know yet whether this is real, but it's one of the more interesting drug-repurposing stories in current neurology.

Sourcing-wise: exenatide is a 39-residue peptide that's been off-patent in some jurisdictions for years, and synthesis is well-established. The challenge is that GLP-1 analogs in general have become heavily counterfeited because of the obesity market, so chain-of-custody and HPLC verification matter more than for most peptides. Don't trust unverified vendors for any GLP-1-family compound right now.

Is it still relevant? Clinically it's basically been replaced by semaglutide and now tirzepatide for diabetes and obesity. Mechanistically and for neuroprotection research it's still very interesting. The Parkinson's signal alone justifies continued attention, and exenatide is the cleanest pure GLP-1R agonist in the toolkit (no GIP cross-activity like tirzepatide).

Evidence: 88
Mechanism: 90
Reliability: 82
Safety: 80
Sourcing: 72
Value: 60
Signal: 75
Staying power: 70

Plain-language summary Intrigue 75 / 100

Exenatide, sold as Byetta and Bydureon, is the original GLP-1 receptor agonist. It is derived from a peptide in Gila monster saliva (exendin-4). The Bydureon formulation is the long-acting once-weekly version. FDA-approved for type 2 diabetes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

GLP-1 receptor agonist (exendin-4)

A synthetic version of the Gila monster venom peptide exendin-4, FDA-approved as Byetta (twice daily) and Bydureon (weekly) for T2DM.

Abstract

Exenatide (Byetta, Bydureon; CAS 141758-74-9; molecular weight 4186.57) is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from Gila monster (Heloderma suspectum) venom. The compound is a GLP-1 receptor agonist with substantial structural difference from human GLP-1, providing resistance to DPP-4 cleavage. Exenatide was the first GLP-1 receptor agonist approved (Byetta, 2005); the extended-release formulation (Bydureon, 2012) provides once-weekly administration. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

GLP-1 receptor agonist; exendin-4 sequence with natural DPP-4 resistance.

Reported research dose ranges

Reported research dose ranges in the literature.

References

DeFronzo RA, et al. Effects of exenatide (synthetic exendin-4) on glycemic control. Diabetes Care 2005.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-193

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Exenatide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs